Efficacy and safety of direct-acting antivirals in elderly with chronic hepatitis C: results from a retrospective cohort study
Background. Seroprevalence of hepatitis C virus infection has increased over the last decade and because
of hepatitis C virus acquisition time and age of most infected persons, the proportion of elderly with CHC is
expected to increase over time. With the approval of direct-acting antivirals (DAAs), treatment access has expanded
to interferon intolerant patient populations, including older age. However, elderly patients, especially
those aged 75 years and older, have been excluded from most clinical trials and few data are available on
safety and efficacy of DAAs in this special population.
Methods. We conducted a retrospective cohort study on three age subgroups of patients (< 65 years; 65-74
years and ≥ 75 years) treated with DAAs between March 2015 and March 2017. Two hundred and sixty-two
patients were followed up with clinical and laboratory evaluations during antiviral therapy.
Results. HCV genotype distribution significantly differed among the three subgroups. Antiviral treatments were
not different between younger and elderly groups. Sofosbuvir-based regimens were used in about 60% of
patients without significant differences among the three age-subgroups. All patients except three achieved
SVR12 (99.3% in elderly vs 98.3% in younger patients). A total of 62 patients (23.7%) showed at least one
adverse event (AE). AEs were not higher in elderly patients.
Conclusions. Our data showed that DAAs in elderly CHC patients were as effective as youngers without any
significant increase of adverse events.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© Società Italiana di Gerontologia e Geriatria (SIGG) , 2018
How to Cite
- Abstract viewed - 43 times
- PDF downloaded - 63 times